Breast imaging and reporting data system (BIRADS) magnetic resonance imaging illustrated cases.

Illustrated cases are presented here, for training the reader to BIRADS MRI. This article offers guidance in integrating findings from the different MR sequences, morphology and kinetics of an abnormal enhancement: report organization, use of lexicon for describing the detected lesion, final assessment with BI-RADS assessment categories.

Breast imaging and reporting data system (BIRADS): magnetic resonance imaging.

This article reviews the technical aspects and interpretation criteria in breast MR imaging based on the first edition of breast imaging and reporting data system (BIRADS) published by the American College of Radiology (ACR) in 2003. In a second article, practical cases will be proposed for training the readers. The major aims of using this lexicon are: first to use a logical and standardized description of MR lesions, secondly to obtain a structured MR report with a clear final impression (BIRADS assessment categories), and thirdly to help comparison between different clinical studies based on similar breast MRI terminology.

Monitoring therapeutic efficacy in breast carcinomas.

The aim of imaging during and after neoadjuvant therapy is to document and quantify tumor response: has the tumor size been accurately measured? Certainly, the most exciting information for the oncologists is: can we identify good or nonresponders, and can we predict the pathological response early after the initiation of treatment? This review article will discuss the role and the performance of the different imaging modalities (mammography, ultrasound, magnetic resonance imaging and FDG-PET imaging) for evaluating this therapeutic response. It is important to emphasize that, at this time, clinical examination and conventional imaging (mammography and ultrasound) are the only methods recognized by the international criteria. Magnetic resonance imaging and FDG-PET imaging are very promising for predicting the response early after the initiation of neoadjuvant chemotherapy.